Medacta Group SA develops, manufactures, and distributes orthopedic and spinal surgery medical devices in Europe, North America, the Asia-Pacific, and internationally. More Details
Solid track record with high growth potential.
Share Price & News
How has Medacta Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MOVE is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MOVE's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
CH Medical Equipment
1 Year Return
CH Medical Equipment
Return vs Industry: MOVE exceeded the Swiss Medical Equipment industry which returned 33.7% over the past year.
Return vs Market: MOVE exceeded the Swiss Market which returned 14.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medacta Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StMedacta Group SA's (VTX:MOVE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
1 month ago | Simply Wall StWe Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
2 months ago | Simply Wall StWhat You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Is Medacta Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MOVE (CHF111.2) is trading below our estimate of fair value (CHF112.27)
Significantly Below Fair Value: MOVE is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: MOVE is good value based on its PE Ratio (54.6x) compared to the Swiss Medical Equipment industry average (62x).
PE vs Market: MOVE is poor value based on its PE Ratio (54.6x) compared to the Swiss market (24.3x).
Price to Earnings Growth Ratio
PEG Ratio: MOVE is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: MOVE is overvalued based on its PB Ratio (12.3x) compared to the CH Medical Equipment industry average (6x).
How is Medacta Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MOVE's forecast earnings growth (22.8% per year) is above the savings rate (-0.3%).
Earnings vs Market: MOVE's earnings (22.8% per year) are forecast to grow faster than the Swiss market (12.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MOVE's revenue (13% per year) is forecast to grow faster than the Swiss market (4.5% per year).
High Growth Revenue: MOVE's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MOVE's Return on Equity is forecast to be high in 3 years time (24.1%)
How has Medacta Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MOVE has high quality earnings.
Growing Profit Margin: MOVE's current net profit margins (12.3%) are higher than last year (3.8%).
Past Earnings Growth Analysis
Earnings Trend: MOVE's earnings have declined by 19.7% per year over the past 5 years.
Accelerating Growth: MOVE's earnings growth over the past year (213%) exceeds its 5-year average (-19.7% per year).
Earnings vs Industry: MOVE earnings growth over the past year (213%) exceeded the Medical Equipment industry -46.3%.
Return on Equity
High ROE: MOVE's Return on Equity (22.5%) is considered high.
How is Medacta Group's financial position?
Financial Position Analysis
Short Term Liabilities: MOVE's short term assets (€217.7M) exceed its short term liabilities (€144.8M).
Long Term Liabilities: MOVE's short term assets (€217.7M) exceed its long term liabilities (€132.4M).
Debt to Equity History and Analysis
Debt Level: MOVE's debt to equity ratio (79.8%) is considered high.
Reducing Debt: Insufficient data to determine if MOVE's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MOVE's debt is well covered by operating cash flow (45.4%).
Interest Coverage: MOVE's interest payments on its debt are well covered by EBIT (18.2x coverage).
What is Medacta Group current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MOVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MOVE's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Francesco Siccardi (43 yo)
Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...
Experienced Management: MOVE's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: MOVE's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medacta Group SA's company bio, employee growth, exchange listings and data sources
- Name: Medacta Group SA
- Ticker: MOVE
- Exchange: SWX
- Founded: 1958
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CHF2.224b
- Shares outstanding: 20.00m
- Website: https://www.medacta.com
Number of Employees
- Medacta Group SA
- Strada Regina, 34
- Castel San Pietro
Medacta Group SA develops, manufactures, and distributes orthopedic and spinal surgery medical devices in Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic mode...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 01:03|
|End of Day Share Price||2021/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.